Bionomics Limited (NASDAQ:BNOX – Get Free Report) was the recipient of a significant decrease in short interest in October. As of October 15th, there was short interest totalling 13,800 shares, a decrease of 81.1% from the September 30th total of 73,000 shares. Based on an average trading volume of 626,600 shares, the short-interest ratio is currently 0.0 days.
Bionomics Price Performance
Shares of BNOX traded down $0.11 during mid-day trading on Friday, hitting $0.25. The stock had a trading volume of 4,017,426 shares, compared to its average volume of 541,273. Bionomics has a fifty-two week low of $0.23 and a fifty-two week high of $3.03. The company’s fifty day simple moving average is $0.50 and its two-hundred day simple moving average is $0.71.
Analysts Set New Price Targets
Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 target price on shares of Bionomics in a research report on Thursday, August 1st.
Hedge Funds Weigh In On Bionomics
An institutional investor recently bought a new position in Bionomics stock. Armistice Capital LLC acquired a new position in shares of Bionomics Limited (NASDAQ:BNOX – Free Report) during the 2nd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 1,226,759 shares of the company’s stock, valued at approximately $941,000. Armistice Capital LLC owned 15.03% of Bionomics as of its most recent SEC filing. 15.90% of the stock is owned by institutional investors and hedge funds.
Bionomics Company Profile
Bionomics Limited, a clinical stage biopharmaceutical company, discovers and develops novel drug candidates for the treatment of central nervous system disorders and cancers. The company's lead drug candidate includes BNC210, a negative allosteric modulator of the a7 nicotinic acetylcholine receptor, which is in phase 2 clinical trial for the treatment of social anxiety disorder and phase 2b to treat post-traumatic stress disorder.
Read More
- Five stocks we like better than Bionomics
- What Are Dividends? Buy the Best Dividend Stocks
- Lam Research Proves Analysts Wrong with a Strong Earnings Report
- What is a Stock Market Index and How Do You Use Them?
- PureCycle: Up 250% in 2024 – Is This Materials Stock Still a Buy?
- Health Care Stocks Explained: Why You Might Want to Invest
- MarketBeat Week in Review – 10/21- 10/25
Receive News & Ratings for Bionomics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bionomics and related companies with MarketBeat.com's FREE daily email newsletter.